Physician profile
Andrew Keller
NPI 1184154973
$1,610.09
in general payments reported to CMS, 2019-2025
22 companies · $584 in 2025
The $584 reported for 2025 was more than what 77% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.69 · 2021: $43.28 · 2022: $118 · 2023: $433 · 2024: $398 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $361.10 | 2023-2025 | Bravos Afterloader System |
| Bioprotect Medical, INC. | $175.72 | 2024-2025 | Bioprotect Balloon Implant System |
| Novocure INC. | $166.12 | 2023-2025 | Optune, Optune Lua (Novottf-200t) |
| Elekta, INC. | $134.26 | 2024 | |
| Boston Scientific Corporation | $110.41 | 2019-2025 | Spaceoar Vue System - 10ml |
| Brainlab, INC. | $99.73 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $93.37 | 2023 | Imfinzi |
| Monteris Medical Corporation | $74.35 | 2023 | Neuroblate |
| Tersera Therapeutics LLC | $48.92 | 2023-2024 | Zoladex |
| Daiichi Sankyo INC. | $42.73 | 2022-2024 | Enhertu |
| Stryker Corporation | $31.58 | 2025 | Optablate |
| Eisai INC. | $30.20 | 2024 | |
| Blue Earth Diagnostics | $29.19 | 2025 | Posluma |
| Bayer Healthcare Pharmaceuticals INC. | $27.31 | 2025 | |
| Sumitomo Pharma America, INC. | $27.31 | 2024 | Orgovyx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $26.08 | 2025 | Loqtorzi |
| Takeda Pharmaceuticals U.S.A., INC. | $25.07 | 2025 | Fruzaqla |
| Progenics Pharmaceuticals, INC. | $24.58 | 2025 | |
| Telix Pharmaceuticals | $22.83 | 2025 | Illuccix |
| Novartis Pharmaceuticals Corporation | $20.90 | 2025 | |
| Merck Sharp & Dohme LLC | $19.89 | 2024 | Keytruda |
| Lilly USA, LLC | $18.44 | 2023 | Verzenio, Jaypirca, Retevmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.